Each year, 1 in 294 newborns is identified with a condition through newborn screening (NBS), which can lead to early treatment and potentially life-saving interventions.
Advances in genomic technologies are expected to broaden the scope of NBS, but the process of expanding screening occurs slowly and inconsistently across the US.
The NBS Expansion Study analyzed current NBS practices and identified four main factors that complicate expansion, averaging a 9.5-year delay for nationwide adoption of new conditions.